Skip to Main Content

Paper Details

The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy.
Hematology Am Soc Hematol Educ Program
0
2023
Author NameAffiliation
Justin M WattsSylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine
  • 1 - 1

Datasets

Release 1.2